Rein Therapeutics (RNTX) Times Interest Earned (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Times Interest Earned of -$16.39 for Q1 2026, down 166.87% year-over-year from $24.52 in Q1 2025, and up 92.07% quarter-over-quarter from -$206.7 in Q4 2025.
Rein Therapeutics (RNTX) Times Interest Earned (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Times Interest Earned for 11 consecutive years, with -$16.39 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned fell 166.87% year-over-year to -$16.39; the TTM figure through Mar 2026 stood at -$157.53 (down 126.44% YoY), while the FY2025 annual figure was -$320.45, down 14887.97% from the prior year.
- Times Interest Earned rose to -$16.39 in Q1 2026 per RNTX's latest filing, from -$206.7 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.06 in Q4 2022 and bottomed at -$996.0 in Q2 2023.
- Historically, Times Interest Earned has averaged -$127.75 across 5 years, with a median of -$15.85 in 2026.
- Annual changes were most pronounced in 2024 — Times Interest Earned surged 99.84% — and 2025, when it sank 14608.79%.
- Rein Therapeutics' Times Interest Earned stood at -$0.06 in 2022, then plunged by 548.65% to -$0.39 in 2023, then plunged by 256.74% to -$1.41 in 2024, then tumbled by 14608.79% to -$206.7 in 2025, then soared by 92.07% to -$16.39 in 2026.
- Business Quant data shows RNTX's Times Interest Earned at -$16.39 in Q1 2026, -$206.7 in Q4 2025, and -$35.9 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -13.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.18 |
| Mar 31, 2026 | -16.39 |
| Dec 31, 2025 | -206.70 |
| Sep 30, 2025 | -35.90 |
| Jun 30, 2025 | -15.30 |
| Mar 31, 2025 | -6.14 |
| Dec 31, 2024 | -1.41 |
| Sep 30, 2024 | -1.80 |
| Jun 30, 2024 | -3.92 |
| Mar 31, 2024 | -0.81 |
| Dec 31, 2023 | -0.39 |
| Jun 30, 2023 | -996.00 |
| Mar 31, 2023 | -501.10 |
| Dec 31, 2022 | -0.06 |
| Sep 30, 2022 | -66.14 |
| Jun 30, 2022 | -79.61 |
| Mar 31, 2022 | -112.28 |
| Dec 31, 2021 | -0.10 |
| Sep 30, 2021 | -15.30 |
| Jun 30, 2021 | -7.31 |